The prophylactic HER-2 vaccines were also effective in preventing metastasis outgrowth, thus indicating that the concepts and the approaches developed for cancer immunoprevention could be effective also in cancer immunotherapy (Nanni et al., 2007). This evidence concerns the gene ERBB2 and cancer.